Online citations, reference lists, and bibliographies.
← Back to Search

Systematic Review And Meta-Analysis Of Multitargeted Tyrosine Kinase Inhibitors In Patients With Intractable Metastatic Colorectal Cancer

Zhenzhen Gao, Chenxi Cao, Y. Bao, Yao-Hua Fan, G. Chen, Peng Fu
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background: The treatment options for intractable metastatic colorectal cancer include regorafenib, trifluridine/tipiracil, and fruquintinib. In this study, we aimed to conduct a network meta-analysis for comparing the efficacy of these agents. Methods: We searched the PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials databases for relevant literature, up to February 2020. The data were collected from randomized controlled trials on regorafenib, trifluridine/tipiracil, or fruquintinib, administered to patients with metastatic colorectal cancer who failed on treatment with oxaliplatin, irinotecan, or fluoropyrimidine. The primary end points, namely, the overall survival and progression-free survival, were analyzed for subsequent network analysis using the Review Manager and Aggregate Data Drug Information System software for performing direct and indirect comparisons. Results: A total of 7 trials were analyzed in this study. Trifluridine/tipiracil and regorafenib proved to be superior to the placebo, with respect to the overall survival (odds ratio: 0.38, 95% confidence interval: 0.27-0.52 for trifluridine/tipiracil; odds ratio: 0.47, 95% confidence interval: 0.26-0.84 for regorafenib) and progression-free survival (odds ratio: 0.18, 95% confidence interval: 0.05-0.67 for trifluridine/tipiracil; odds ratio: 0.06, 95% confidence interval: 0.04-0.09 for regorafenib). Regorafenib (80 mg) was superior to the placebo in terms of the overall survival and progression-free survival and inferior to trifluridine/tipiracil and fruquintinib. Network analysis revealed that the efficacy of trifluridine/tipiracil and fruquintinib was fundamentally similar, and both the agents were superior to regorafenib. Conclusion: Regorafenib (80 mg) was superior to the placebo, but inferior to 160 mg regorafenib, trifluridine/tipiracil, and fruquintinib. This study further revealed that the efficiency of trifluridine/tipiracil and fruquintinib is identical, but their toxicity profiles are different.
This paper references
10.1016/s1470-2045(19)30827-7
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
P. Pfeiffer (2020)
10.1001/jama.2018.7855
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial
J. Li (2018)
10.1016/j.jclinepi.2010.07.015
GRADE guidelines: 3. Rating the quality of evidence.
Howard Balshem (2011)
10.1016/S1470-2045(12)70345-5
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
T. Yoshino (2012)
10.1186/s13045-016-0384-9
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
R. Xu (2017)
10.1093/ANNONC/MDZ155.079
Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 - UCGI 35 - REGIRI).
E. Samalin (2019)
10.1007/978-3-642-78225-1
Colorectal Cancer
J. Hardcastle (1993)
10.1016/j.ccell.2019.07.010
The Dual Roles of the Atypical Protein Kinase Cs in Cancer.
M. Reina-Campos (2019)
A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. Oncologist
MB Sonbol (2019)
10.1056/NEJMoa1414325
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
R. Mayer (2015)
10.1016/S1470-2045(15)70156-7
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
J. Li (2015)
10.1038/s41598-020-58357-0
Methylenetetrahydrofolate reductase C677T polymorphism is not associated with the risk of nonsyndromic cleft lip/palate: An updated meta-analysis
M. Imani (2020)
REVERCE: a randomized Phase II trial of regorafenib - cetuximab for mCRC previously treated with chemotherapy
Y Kagawa (2018)
10.1007/s00198-020-05360-w
Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and meta-analysis
Y. Wang (2020)
10.1016/S1470-2045(19)30272-4
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
T. Bekaii-Saab (2019)
10.1053/j.gastro.2019.11.026
Optimizing the Quality of Colorectal Cancer Screening Worldwide.
M. Kaminski (2019)
10.12659/MSM.918411
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials
J. Chen (2019)
10.1016/j.jclinepi.2017.10.005
Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis.
R. Brignardello-Petersen (2018)
10.1186/s12885-015-1503-7
STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer
B. Chibaudel (2015)
10.1200/JCO.2017.76.7145
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.
Shun Lu (2018)
10.1634/theoncologist.2019-0189
A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
M. Sonbol (2019)
10.1016/S0140-6736(12)61900-X
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
A. Grothey (2013)
10.1007/s00384-019-03477-x
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Q. Zhang (2019)
Randomized, Double-Blind, PlaceboControlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous NonSmall-Cell Lung Cancer
S Lu (2018)
10.1200/JCO.2017.74.3245
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
J. Xu (2018)
10.1007/978-3-642-59945-3_9
Chemoprevention of colorectal cancer.
J. Faivre (1999)
10.1136/bmj.g5630
A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis
M. Puhan (2014)
10.1053/j.gastro.2019.06.043
Strategies for Colorectal Cancer Screening.
U. Ladabaum (2019)
10.1016/j.ijid.2020.03.064
Multidrug resistant tuberculosis treatment outcome in children in developing and developed countries: A systematic review and meta-analysis.
H. H. Tola (2020)
10.1200/JCO.2019.37.4_SUPPL.619
A systematic review and network meta-analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer.
M. Sonbol (2019)
Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous NonSmall-Cell Lung Cancer
S Lu (2018)
Regorafenib doseoptimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
TS Bekaii-Saab (2019)
10.1016/j.clcc.2018.02.005
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy
R. Petrioli (2018)
10.1097/PAI.0b013e31827ea79e
Pathways of Colorectal Carcinogenesis
M. Arends (2013)
10.1053/j.gastro.2018.12.045
The Role of the Microbiome in Immunologic Development and its Implication For Pancreatic Cancer Immunotherapy.
V. Sethi (2019)
10.2217/fon-2019-0786
First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.
T. André (2020)



Semantic Scholar Logo Some data provided by SemanticScholar